Abstracts Archive - Page 37 of 2607 - ACR Meeting Abstracts

Abstract Number: 0315 • ACR Convergence 2025
Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.
Avanika Mahajan¹, Caroyln Harvey², Andy Abril³ and Megan Sullivan⁴, ¹Mayo Clinic, Scottsdale, ²Mayo Clinic, Phoenix, AZ, ³Mayo Clinic Florida, Jacksonville, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Erosive hand osteoarthritis (EHOA) is an inflammatory subtype of hand OA that causes subchondral bone erosion and cortical destruction, often resulting in debilitating symptoms.…
Abstract Number: 0265 • ACR Convergence 2025
Influence of Menopausal Status on Coronary Artery Calcium Burden and Cardiovascular Computed Tomography Abnormalities in Inflammatory Arthritis
Mohammed Mohammed¹, Bindee Kuriya², Lihi Eder¹, Elsie Nguyen³, Shadi Ahktari⁴, Paula Harvey⁵, Wei Wu⁶ and Sohan Shahab⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University of Toronto Department of Medicine and Women's College Hospital, Toronto, Canada, ⁵University of Toronto Department of Medicine and Women's College Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, Canada, ⁷Women’s College Research Institute, Women’s College Hospital, Toronto, Canada
Background/Purpose: Patients with inflammatory arthritis (IA) have increased cardiovascular risk. Coronary artery calcium (CAC) scoring by computed tomography (CT) detects early coronary disease and structural…
Abstract Number: 0252 • ACR Convergence 2025
Capillaroscopic Signatures in Autoimmune Rheumatic Diseases: Unveiling Patterns in Systemic Sclerosis, Polyautoimmunity, and PAH
María Paula Carrillo¹, Juan Esteban Bedoya-Loaiza¹, Claudia Ibáñez-Antequera¹, Laura Gallego¹, Alejandro Escobar¹, Adriana Rojas-Villarraga² and Jairo Cajamarca-Baron³, ¹Fundacion universitaria de ciencias de la salud, Bogota, Distrito Capital de Bogota, Colombia, ²Fundacion Universitaria de Ciencias de la salud, Bogotá, Distrito Capital de Bogota, Colombia, ³Fundacion universitaria de ciencia de la Salud, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Nailfold capillaroscopy is a fundamental tool in rheumatology for assessing capillary morphology, allowing the differentiation between primary and secondary Raynaud’s phenomenon, identifying risks associated…
Abstract Number: 0305 • ACR Convergence 2025
From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
Vaidehi Kothari¹, Eaman Alhassan², Kevin Renz Ambrocio¹, Bonny Rockette-Wagner³, Chester V. Oddis¹, Kendrea (Focht) Garand¹ and Rohit Aggarwal⁴, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³University of Pittsburgh, PITTSBURGH, ⁴University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…
Abstract Number: 0261 • ACR Convergence 2025
Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data
Daphne Guinn¹, Linchen He², Yuru Ren¹, Valeriy Korostyshevskiy¹ and Robert Beckman¹, ¹Georgetown University, Washington, ²Novartis, East Hanover
Background/Purpose: Basket trials group together participants who share a common biomarker or disease pathway across several diseases or phenotypes in a single clinical study. Such…
Abstract Number: 0331 • ACR Convergence 2025
Safety and Efficacy of Colchicine in Osteoarthritis: A Systematic Review and Meta-Analysis of 6,965 Patients
Mohamed Abdelsalam¹, Bassant Elaraby Elsayed Badwy², Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

Background/Purpose: Osteoarthritis (OA) is the most common joint disease, that leads to significant pain and affects quality of life, particularly in older adults. Current treatments…
Abstract Number: 0318 • ACR Convergence 2025
Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study
Cheng Li¹, Jing wu², Yuqing Zhang³, Hongyi He⁴, Ying Hu⁵, Jie Wei⁶, Guanghua Lei⁶ and Chao Zeng⁶, ¹Xiangya Hospital, Changsha, China (People's Republic), ²Xiangya Hospital, chagnsha, Hunan, China (People's Republic), ³Massachusetts General Hospital, Quincy, MA, ⁴Xiangya Hospital Central South University, Changsha, China (People's Republic), ⁵Xiangya School of Public Health Central South University, changsha, China (People's Republic), ⁶Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic)
Background/Purpose: Lipoprotein subclasses play diverse roles in health and disease. Although lipoproteins have been implicated in knee osteoarthritis (KOA), the relationship between lipoprotein subclasses and…
Abstract Number: 0281 • ACR Convergence 2025
Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies
Anja Srpcic¹, Manca Ogric¹, Sasa Cucnik¹, Sergej Pirkmajer², Katja Lakota¹ and Katja Perdan Pirkmajer¹, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoinflammatory diseases that affect muscle tissue, often leading to muscle atrophy, weakness and myalgia.…
Abstract Number: 0255 • ACR Convergence 2025
Clearing the Smoke: Association Between Cannabis Use and Autoimmune Disease Incidence in a Retrospective Cohort Analysis
Justin Riley Lam¹, Emmanuel Otabor², Laith Alomari², Esteban Kosak Lopez², Maxim Barnett² and Shahrzad Abdollahi³, ¹Albert Einstein Medical Center, Philadelphia, PA, ²Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ³Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Cannabis use has increased substantially in the past decades, with legalization expanding across the U.S. Despite its known therapeutic potential, the immunomodulatory effects of…
Abstract Number: 0001 • ACR Convergence 2025
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Gang Bian¹, Tengteng Li¹, Huiling Liu², Zaoshun Hu², Peng Chen¹, Jay Mei³ and Bing Hou³, ¹Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), ²Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), ³Antengene Corporation, Shanghai, China (People's Republic)
Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…
Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Benjamin Jones¹, Miles Smith², Rufei Lu², Carla Guthridge², Susan Macwana², Wade DeJager³, Nancy Olsen⁴, Catriona Wagner⁵, Judith James², David Karp⁶ and Joel Guthridge², ¹Oklahoma State University, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁶UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…
Abstract Number: 0221 • ACR Convergence 2025
A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network
Grant Cannon¹, Beth Wallace², Deana Lazaro³, Pascale Schwab⁴, Paul Monach⁵, Ankoor Shah⁶, Gail Kerr⁷, Andreas Reimold⁸, Joshua Baker⁹, Gary Kunkel¹⁰, Katherine Wysham¹¹, Liron Caplan¹², John Richards¹³, Aleksander Lenert¹⁴, Andrew Jones¹⁵, Ted Mikuls¹⁶, Maria I. ("Maio") Danila¹⁷, Bryant England¹⁶, Brian Sauer¹⁸, Jorge Rojas¹⁹ and Isaac Smith²⁰, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³VA New York Harbor Healthcare system, Short Hills, NJ, ⁴VA Portland and Oregon Health & Science University, Portland, OR, ⁵VA Boston Healthcare System, Boston, MA, ⁶Duke University, Durham, NC, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Dallas VA Medical Center, Dallas, TX, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ¹²Rocky Mountain Regional VAMC, Aurora, CO, ¹³Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁴University of Iowa, Iowa City, IA, ¹⁵VA Saint Louis and Washington University, Saint Louis, ¹⁶University of Nebraska Medical Center, Omaha, NE, ¹⁷University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁸Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁹VA Puget Sound Health Care System, Seattle, WA, ²⁰Duke University Hospital, Durham, NC
Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of…
Abstract Number: 0362 • ACR Convergence 2025
Drug Persistence of IL-17A Inhibitors Among Patients with PsA: Real-World Data from the CorEvitas PsA/SpA Registry
Philip J. Mease¹, Nicole Middaugh², Maya Marchese³, Skyler Peterson³, Burcu Ertugrul Vardar⁴, Russel Burge⁵, Natalia Bello⁶, Marcus Ngantcha⁷, Joseph F Merola⁸, Louis Bessette⁹ and Alexis Ogdie¹⁰, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, LLC, Waltham, ⁴Eli Lilly Cork GBS Ltd, Dublin, Dublin, Ireland, ⁵Eli Lilly and Company, Indianapolis, ⁶Eli Lilly, Indianapolis, IN, ⁷Eli Lilly GBS Cork Ltd, Cork, Ireland, ⁸Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: IL-17A inhibitors (IL-17Ai) are considered recommended biologic therapies for PsA per current treatment guidelines1,2. Real-world evidence (RWE) studies on IL-17Ai drug persistence among patients…
Abstract Number: 0368 • ACR Convergence 2025
Factors Associated with Patient Acceptability of Rheumatology Care Delivered by Telemedicine
Hareem Farooq¹, Lesley Jackson¹, Rahima Begum², Gary Cutter², Kenneth Saag³, Jinoos Yazdany⁴ and Maria I. ("Maio") Danila⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴UCSF, San Francisco, CA, ⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Home-based telemedicine is an efficient healthcare delivery approach. A recent randomized clinical trial (RCT) found that in-person visits may be preferred among rheumatology patients.…
Abstract Number: 0372 • ACR Convergence 2025
Development and Implementation of a Remote Educational Program to Optimize Safe Medication Use in Older Veterans with Rheumatic Diseases
Maria Romero Noboa¹, Hannah Howell², Angelo Gaffo³ and Maria I. ("Maio") Danila⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁴University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Symptomatic treatment in rheumatic and musculoskeletal diseases (RMDs) – including glucocorticoids (GCs) and non-steroidal anti-inflammatory drugs (NSAIDs) – can result in improved quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].